Teliso-V, a MET-targeted ADC, combined with osimertinib, reported an ORR of 50% and a mPFS of 6.8 months in patients with MET overexpressed (MET 3 or higher staining in ≥25% tumor cells) EGFR-mutant NSCLC progression on osimertinib.30 This evidence concerns the gene EGFR and neoplasm.